---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-256101"
form_type: "8-K"
ticker: "FULC"
cik: "0001680581"
company_name: "Fulcrum Therapeutics, Inc."
filed_at: "2024-11-12T23:59:59+00:00"
generated_at: "2026-05-30T02:01:06.154905+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.35
calibrated_materiality_score: 0.35
confidence: "high"
source: SEC EDGAR
---

# Director James Collins resigns; Rachel King appointed to board of Fulcrum Therapeutics

## Summary
- James J. Collins resigned as Class II director effective Nov 12, 2024, not due to any disagreement with the company or board.
- Board appointed Rachel King as Class II director to fill the vacancy; term expires at 2027 annual meeting.
- King is independent and will serve on Compensation & Human Capital Management Committee.
- King receives standard non-employee director compensation including option for 60,000 shares at $3.64 per share.

## SEC filing metadata
- accession: 0001193125-24-256101
- form_type: 8-K
- ticker: FULC
- cik: 0001680581
- company_name: Fulcrum Therapeutics, Inc.
- filed_at: 2024-11-12T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.35
- calibrated_materiality_score: 0.35
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1680581/000119312524256101/0001193125-24-256101-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1680581/000119312524256101/d875361d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-256101
- JSON: https://secwatch.observer/filing/0001193125-24-256101.json
- Plain text: https://secwatch.observer/filing/0001193125-24-256101.txt

## Key facts
- Executive change
  Rachel King was appointed as director at Fulcrum Therapeutics, Inc..
  - Action: appointed
  - Role: director
  source text: On November 12, 2024, the Board, upon the recommendation from the Nominating and Corporate Governance Committee, appointed Rachel King as a member of the Board, with immediate effect to fill the vacancy created by Dr. Collins' resignation.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1680581/000119312524256101/0001193125-24-256101-index.htm
- Executive change
  James J. Collins resigned as director at Fulcrum Therapeutics, Inc..
  - Action: resigned
  - Role: director
  source text: On November 12, 2024, James J. Collins, a Class II director, notified the board of directors, or the Board, of Fulcrum Therapeutics, Inc., or Fulcrum, of his decision to resign as a member of the Board and all committees thereof, with immediate effect.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1680581/000119312524256101/0001193125-24-256101-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.